204 related articles for article (PubMed ID: 24646487)
1. "It's the economy, stupid": strategies for improved cost containment in cancer treatment.
Sleijfer S
Clin Pharmacol Ther; 2014 Apr; 95(4):365-7. PubMed ID: 24646487
[TBL] [Abstract][Full Text] [Related]
2. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
3. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
4. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
McGuire A; Drummond M; Martin M; Justo N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
[TBL] [Abstract][Full Text] [Related]
5. Valuing end-of-life care in the United States: the case of new cancer drugs.
Sorenson C
Health Econ Policy Law; 2012 Oct; 7(4):411-30. PubMed ID: 23079300
[TBL] [Abstract][Full Text] [Related]
6. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
7. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
8. [Innovative therapy, early and cost-benefit assessment].
Dierks C
Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
[No Abstract] [Full Text] [Related]
9. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
10. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
11. [The cost of chemotherapy].
Lévy C; Bonastre J
Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
[TBL] [Abstract][Full Text] [Related]
12. Era of personalized medicine may herald end of soaring cancer costs.
Keogh B
J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
[No Abstract] [Full Text] [Related]
13. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
14. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
15. Seeking value as cancer drug costs soar.
Bender E
Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
[TBL] [Abstract][Full Text] [Related]
16. Optional copayments on anti-cancer drugs.
van de Vooren K; Curto A; Garattini L
BMJ; 2013 Jan; 346():f349. PubMed ID: 23347986
[No Abstract] [Full Text] [Related]
17. Inequalities in oncology care: Economic consequences of high cost drugs.
Niezen MG; Stolk EA; Steenhoek A; Uyl-De Groot CA
Eur J Cancer; 2006 Nov; 42(17):2887-92. PubMed ID: 16979891
[TBL] [Abstract][Full Text] [Related]
18. Innovative cancer therapies: putting costs into context.
Khayat D
Cancer; 2012 May; 118(9):2367-71. PubMed ID: 21918962
[TBL] [Abstract][Full Text] [Related]
19. Ethical and value issues in insurance coverage for cancer treatment.
Brock DW
Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
[TBL] [Abstract][Full Text] [Related]
20. Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009.
Savage P
J Oncol Pharm Pract; 2012 Mar; 18(1):52-6. PubMed ID: 21109615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
